ReviewDrug design, development and therapy2016
Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Review in Drug design, development and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- Biological research on the occurrence and development of multiple myeloma and its treatment.Immunity, inflammation and disease · 2023Pooled it
- The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.Pharmacology & therapeutics · 2020Pooled it
- Nanoparticle-Based delivery of proteasome inhibitors for glioblastoma Therapy: Strategies to overcome Blood-Brain barrier and therapeutic resistance.Biochemical pharmacology · 2026Review
- Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report.Blood neoplasia · 2026Article
- Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications.Translational oncology · 2026Review
- Chemical and Biocatalytic Synthesis of Capsaicinoids and Capsinoids: An Updated Review.Biomolecules · 2026Review
- Amyloid Light Chain Proteins in Cardiovascular Disease: Pathogenesis and Emerging Therapies for Cardiac Amyloidosis.Pharmaceutical research · 2025Review
- Targeting the Ubiquitin-Proteasome System for Cancer.MedComm · 2025Review
- Recent Development of Boron-Containing Small-Molecule Anticancer Agents.ACS pharmacology & translational science · 2025Review
- Potential of Boronic Acid Derivatization and Activity in Agrochemical Discovery.Molecules (Basel, Switzerland) · 2025Review
- Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literature.Annals of hematology · 2025Review
- Natural products that target p53 for cancer therapy.Journal of natural medicines · 2025Review
- Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database.Scientific reports · 2025Article
- Clinical use and toxicities of bortezomib in pediatric patients: a systematic review.Frontiers in pharmacology · 2025Review
- Gastrointestinal toxicities of proteasome inhibitor therapy.Journal of cancer research and clinical oncology · 2024Article
- Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma.Cancer medicine · 2024Article
- Role of Immune Cells and Immunotherapy in Multiple Myeloma.Life (Basel, Switzerland) · 2024Review
- Synthesis of Boron-Containing Nucleoside Analogs.The Journal of organic chemistry · 2024Article
- A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan.Annals of hematology · 2024Observational
- The proteasome as a drug target for treatment of parasitic diseases.Advances in parasitology · 2024Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Despite the significant therapeutic advances achieved with proteasome inhibitors (PIs) such as bortezomib and carfilzomib in prolonging the survival of patients with multiple myeloma, the development of drug resistance, peripheral neuropathy, and pharmacokinetic limitations continue to pose major challenges when using these compounds. Ixazomib is a second-generation PI with improved activity over other PIs. Unlike bortezomib and carfilzomib, which are administered by injection, ixazomib is the first oral PI approved by US Food and Drug Administration. This review discusses the biochemical properties, mechanisms of action, preclinical efficacy, and clinical trial results leading to the US Food and Drug Administration approval of ixazomib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.